VioQuest to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
20 oct. 2005 08h00 HE
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 20, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) has accepted an invitation to speak at the C.E. Unterberg, Towbin Emerging Growth Life Sciences...
VioQuest Completes Merger with Greenwich Therapeutics; Acquires Oncology Compounds
19 oct. 2005 08h00 HE
|
VioQuest Pharmaceuticals
Raises $8.4 Million in Private Placement
Acquisition Establishes Strong Pipeline of Phase I/II Targeted
Oncology Therapeutics
MONMOUTH JUNCTION, N.J. Oct. 19,...
VioQuest to Present at BIO InvestorForum 2005
17 oct. 2005 10h28 HE
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 17, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH), will be presenting at the BIO InvestorForum 2005 Conference at 11:20 AM PST Thursday, October 20th...
VioQuest Pharmaceuticals Named One of 50 Fastest Growing Companies in New Jersey by 'New Jersey's Finest'
12 oct. 2005 09h10 HE
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 12, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH) was named among "New Jersey's 50 Finest" by NJBIZ Magazine. The Company was honored in an awards...
VioQuest Pharmaceuticals Reports 45 Percent Increase in Revenue for Fiscal Third Quarter 2005
05 oct. 2005 08h00 HE
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Oct. 5, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) reported revenue of approximately $533,000 for the third quarter of 2005 compared to $367,000 for the...
VioQuest Pharma Subsidiary Signs License Agreement with Merck to Supply Chiral Catalysts and Ligands
15 sept. 2005 08h00 HE
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J., Sept. 15, 2005 (PRIMEZONE) -- VioQuest's subsidiary Chiral Quest, Inc., (OTCBB:VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the...
VioQuest's Proposed Drug Acquisition Candidate Enters Phase I Clinical Trial at Cleveland Clinic Cancer Center
13 sept. 2005 09h10 HE
|
VioQuest Pharmaceuticals
MONMOUTH JUNCTION, N.J, Sept. 13, 2005 (PRIMEZONE) -- The Cleveland Clinic Taussig Cancer Center has initiated patient enrollment for a Phase I clinical trial of sodium stibogluconate (SSG), an...